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abstract
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall
survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients
with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-
ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov:
NCT02578680).
METHODS Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab
(n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab
or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination
group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by
central review. No alpha was assigned to this updated analysis.
RESULTS As of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was
22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the
placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1
to 9.9) months and 4.9 (4.7 to 5.5) months, respectively (HR, 0.48; 95%CI, 0.40 to 0.58). Median (95%CI) time
from randomization to objective tumor progression on next-line treatment or death from any cause, whichever
occurred first (progression-free-survival-2; PFS-2) was 17.0 (15.1 to 19.4) months and 9.0 (7.6 to 10.4) months,
respectively (HR, 0.49; 95% CI, 0.40 to 0.59). OS and PFS benefits with pembrolizumab were observed re-
gardless of PD-L1 expression or presence of liver/brain metastases. Incidence of grade 3-5 adverse events was
similar in the pembrolizumab-combination (71.9%) and placebo-combination (66.8%) groups.
CONCLUSION First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially
improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain
metastases, with manageable safety and tolerability.
J Clin Oncol 38:1505-1517. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Until the advent of immunotherapy, first-line treatment
of patients with advanced nonsquamous non‒small-
cell lung cancer (NSCLC) without an EGFR/ALK alter-
ation was platinum-based chemotherapy, with addition
of bevacizumab as an option in select patients.1,2 The
introduction of pembrolizumab, an anti‒programmed
death-1 (PD-1) monoclonal antibody, has altered the
treatment paradigm for patients with NSCLC. Pem-
brolizumab has shown efficacy in first-line therapy of
advanced/metastatic NSCLC both when administered
as monotherapy in patients with programmed
death-ligand1(PD-L1) tumorproportionscore (TPS)$ 50%3
and $ 1%4 and when administered in combination
with platinum-based chemotherapy regardless of tumor
PD-L1 expression.5-7 In an analysis of the randomized,
double-blind, phase III KEYNOTE-189 study conducted
with a median follow-up of 10.5 months, pembrolizumab
plus pemetrexed-platinum significantly improved overall
survival (OS; hazard ratio [HR], 0.49; 95%CI, 0.38 to 0.64;
P , .001), progression-free survival (PFS; HR, 0.52;
95%CI, 0.43 to 0.64; P, .001), and objective response
rate (ORR; 47.6% v 18.9%; P , .001) compared with
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metastatic NSCLC without sensitizing EGFR/ALK alterations,
regardless of PD-L1 TPS.6 Toxicity with pembrolizumab plus
pemetrexed-platinum was manageable.
In this updated analysis from KEYNOTE-189, we evaluated
efficacy and safety with approximately 10 additional cal-
endar months of follow-up from the first interim analysis
data cutoff date. Extrapulmonary metastases to sites such
as the liver and brain frequently occur in metastatic NSCLC
and are associated with a poor prognosis8,9; whether such
metastases alter the magnitude of benefit with immuno-
therapy has been uncertain.10 Therefore, we assessed
outcomes among patients with liver/brain metastases. Finally,
to characterize the treatment effect of pembrolizumab on the
next line of therapy, we conducted a protocol-specified ex-
ploratory analysis of progression-free survival-2 (PFS-2).11
METHODS
Patients and Study Design
The study design has been previously described.6 Briefly,
patients had previously untreated pathologically confirmed
metastatic nonsquamous NSCLC without sensitizing EGFR/
ALK alterations, Eastern Cooperative Oncology Group
performance status of 0/1, and$ 1 measurable lesion, and
provided a tumor sample for PD-L1 evaluation. Exclusion
criteria included symptomatic CNS metastases, history of
noninfectious pneumonitis requiring glucocorticoids, active
autoimmune disease, or systemic immunosuppressive
therapy. All patients provided written informed consent;
study procedures were approved by an independent ethics
committee at each site. Patients were randomly assigned
(2:1) to receive either 200 mg pembrolizumab or saline
placebo every 3 weeks for up to 35 cycles. Randomization
was stratified by tumor PD-L1 TPS ($ 1% v, 1%), choice
of platinum (cisplatin v carboplatin), and smoking history
(never v former/current). All patients received pemetrexed
and investigators’ choice of cisplatin or carboplatin every
3 weeks for 4 cycles followed by pemetrexed maintenance
therapy every 3 weeks. Patients who received placebo
could cross over to pembrolizumab monotherapy at the
time of disease progression (as verified by a blinded, in-
dependent central radiologic review [BICR]) if they met
eligibility criteria.
Assessments
Tumor tissue samples obtained by core-needle or exci-
sional biopsy at the time of diagnosis were fixed in formalin
and centrally assessed for PD-L1 expression using the
PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies,
Carpinteria, CA). PD-L1 expression was categorized by TPS
(the percentage of tumor cells with membranous PD-L1
staining). Tumor imaging occurred at weeks 6 and 12,
every 9 weeks through week 48, and every 12 weeks after
week 48. Patients with brain metastases underwent im-
aging of the brain at the same intervals. Response was
assessed per RECIST (version 1.1) by BICR. Survival was
assessed every 12 weeks after discontinuation of study
treatment. Adverse events (AEs), including AEs of special
interest, through 30 days (90 days for serious AEs) after the
last treatment dose or until start of new therapy were graded
according to the National Cancer Institute–Common Ter-
minology Criteria for Adverse Events (version 4.0).
Endpoints
The dual primary endpoints were OS and PFS; secondary
endpoints were ORR, duration of response (DOR), and
safety. Efficacy analyses in patients with baseline liver or
brain (prespecified) metastases were exploratory. PFS-2,
which was defined as the time from randomization to
objective tumor progression on next-line treatment (in-
cluding subsequent anti‒PD-[L]1 therapy) or death from
any cause, whichever occurs first, was a protocol-specified
exploratory endpoint. Events for PFS-2 analysis were
characterized as time of investigator-assessed disease
progression that led to cessation of second-line therapy,
start of third-line therapy for patients who stopped second-
line therapy without disease progression, and time of death
for patients who either stopped second-line therapy without
disease progression and did not initiate third-line therapy or
did not receive second-line therapy. Patients were cen-
sored for PFS-2 at the time of last known survival if they
were alive and either had not received second-line therapy
or had stopped second-line therapy without disease pro-
gression and had not initiated third-line therapy.
Statistical Analyses
Efficacy analyses were performed in the intention-to-treat
(ITT) population, which included all randomly assigned
patients; safety analyses were performed in the as-treated
population, which included all randomly assigned patients
who received $ 1 dose of therapy. The Kaplan-Meier
method was used to estimate OS, PFS, and PFS-2. A
stratified Cox proportional hazards model with Efron’s
method of tie handling was used to determine HRs and
95% CIs. Stratification factors used for randomization were
applied. Analyses were not controlled for multiplicity; no
alpha was assigned to this updated analysis.
RESULTS
Patients and Treatments
Overall, 616 patients were randomly assigned to pem-
brolizumab plus pemetrexed-platinum (n = 410) or placebo
plus pemetrexed-platinum (n = 206). Patient demographics
and baseline disease characteristics were generally similar
between groups (Table 1). The proportions of patients in PD-
L1 TPS subgroups (, 1%, 1%-49%, and $ 50%) were
similar between treatment groups; approximately one third of
patients had TPS , 1%. At baseline, 66 (16.1%) and 73
(17.8%) patients in the pembrolizumab-combination group
had liver and brain metastases, respectively, versus 49
(23.8%) and 35 (17.0%), respectively, in the placebo-
combination group.
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At data cutoff (September 21, 2018), median (range) study
follow-up (time from randomization to database cutoff) was
23.1 (18.6 to 30.9) months, and median (range) time from
randomization to death or database cutoff, whichever oc-
curred first, was 18.7 (0.2 to 30.9) months. Mean (standard
deviation) treatment duration was 9.8 (7.8) months in the
pembrolizumab-combination group and 6.2 (5.7) months
in the placebo-combination group (Data Supplement,
online only). In the pembrolizumab-combination group, 58
patients (14.1%) remained on $ 1 component of study
therapy compared with 7 patients (3.4%) in the placebo-
combination group (Fig 1). An additional 58 patients
(14.1%) in the pembrolizumab-combination group and
8 patients (3.9%) in the placebo-combination group had
stopped all study treatment and were alive without sub-
sequent treatment, including 36 (8.8%) and 4 (1.9%),
respectively, who were without disease progression. Twenty-
four patients in the pembrolizumab-combination group and
1 in the placebo-combination group completed 35 cycles of
pembrolizumab or placebo, respectively; 12 patients
remained on pemetrexed only (all in pembrolizumab-
combination group). In the ITT population, 183/410 pa-
tients (44.6%) in the pembrolizumab-combination group
and 122/206 (59.2%) in the placebo-combination group
received $ 1 subsequent therapy; 84 patients (40.8%) in
the placebo-combination group crossed over on-study to
pembrolizumab monotherapy, and 111 received any sub-
sequent anti–PD-(L)1-therapy (effective crossover rate,
53.9%; Data Supplement).
OS and PFS
At the time of data cutoff, 213 patients (52.0%) in the
pembrolizumab-combination group and 144 patients (69.9%)
in the placebo-combination group had died. Median (95% CI)
OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-
combination group and 10.7 (8.7 to 13.6) months in the
placebo-combination group (HR, 0.56; 95% CI, 0.45 to 0.70;
Fig 2A); estimated 24-month OS rates were 45.5%and 29.9%,
respectively. The addition of pembrolizumab provided survival
benefit irrespective of PD-L1 expression (Figs 2B-2D); Data
Supplement).
Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9
(4.7 to 5.5) months in the pembrolizumab-combination
and placebo-combination groups, respectively (HR, 0.48;
95% CI, 0.40 to 0.58; Fig 3A); estimated 24-month PFS
rates were 20.5% and 1.5%. As with OS, PFS benefit with
the addition of pembrolizumab was observed irrespective of
PD-L1 expression (Figs 3B-3D); Data Supplement).
TABLE 1. Patient Demographics and Baseline Disease Characteristics
Characteristic Pembrolizumab Combination (n = 410) Placebo Combination (n = 206)
Age, median (range), years 65.0 (34-84) 63.5 (34-84)
Male 254 (62.0) 109 (52.9)
ECOG performance status
0 186 (45.4) 80 (38.8)
1 220 (53.7) 125 (60.7)
2 1 (0.2) 0
Smoking status
Former or current 362 (88.3) 181 (87.9)
Never 48 (11.7) 25 (12.1)
Liver metastases 66 (16.1) 49 (23.8)
Brain metastases 73 (17.8) 35 (17.0)
Previously treated 43 (10) 23 (11)
PD-L1 TPS
, 1% 127 (31.0) 63 (30.6)
1%-49% 128 (31.2) 58 (28.2)
$ 50% 132 (32.2) 70 (34.0)
Could not be evaluated 23 (5.6) 15 (7.3)
Previous therapy
Thoracic radiotherapy 29 (7.1) 19 (9.2)
Neoadjuvant therapy 5 (1.2) 6 (2.9)
Adjuvant therapy 25 (6.1) 14 (6.8)
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; TPS, tumor proportion scale.
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Objective Response
Confirmed objective response occurred in 197 (48.0%)
patients in the pembrolizumab-combination group (com-
plete response [CR], n = 4; partial response [PR], n = 193)
and 40 patients (19.4%) in the placebo-combination group
(CR, n = 1; PR, n = 39; Table 2). Median (range) DOR was
12.4 (1.1+ to 29.0+ months and 7.1 (2.4 to 22.0+) months
in the pembrolizumab-combination and placebo-combination
groups, respectively (+ indicates no progressive disease by the
time of last disease assessment; Table 2). Ninety patients
(52.3%) in the pembrolizumab-combination group and 8
(26.9%) in the placebo-combination group had estimated
DOR $ 12 months. Response rate and DOR were higher in
the pembrolizumab-combination group irrespective of PD-L1
expression (Table 2; Data Supplement).
Progression-Free Survival-2
Median (95% CI) PFS-2 was 17.0 (15.1 to 19.4) months in
the pembrolizumab-combination group and 9.0 (7.6 to
10.4) months in the placebo-combination group (HR, 0.49;
95% CI, 0.40 to 0.59; Fig 4A). PFS-2 benefit associated
with pembrolizumab was observed irrespective of PD-L1
expression (Figs 4B and 4C).
Outcomes in Patients With Baseline Liver or
Brain Metastases
As in the overall population, an OS benefit was observed
in the pembrolizumab-combination group versus the
placebo-combination group in the subgroups of patients
with liver (n = 115) or brain (n = 108) metastases (Figs 5A-
5D). HRs for OS with pembrolizumab-combination versus
placebo-combination were similar among patients with
(0.62; 95% CI, 0.39 to 0.98) and without (0.58; 95% CI,
0.45 to 0.74) liver metastases (Figs 5A and 5B) and those
with (0.41; 95%CI, 0.24 to 0.67) and without (0.59; 95%CI,
0.46 to 0.75) brain metastases (Figs 5C and 5D). PFS was
also improved among patients with and without liver (Data
Supplement) and brain metastases (Data Supplement).
Adverse Events
All-cause AEs occurred in 404 patients (99.8%) in the
pembrolizumab-combination group and 200 (99.0%) in
the placebo-combination group (Table 3). Grade 3-5 AEs
occurred in 291 (71.9%) and 135 patients (66.8%), re-
spectively. Compared with initial analysis, 2 additional
patients in each group had all-cause AEs leading to death
(pembrolizumab-combination: spinal fracture and general
physical health deterioration, n = 1 each; total, n = 29
[7.2%]; placebo-combination: respiratory failure and
bronchitis, n = 1 each; total, n = 14 [6.9%]; Data Sup-
plement); 8 patients (2.0%) in the pembrolizumab-
combination group died of AEs attributed to study treat-
ment. AEs of acute kidney injury occurred in 25 patients
(6.2%) in the pembrolizumab-combination group and
occurred in 1 patient (0.5%) in the placebo-combination
group. Since the prior analysis, no new patients who died as
a result of the AE of acute kidney injury occurred in the
pembrolizumab-combination group. The most frequently
occurring AEs in both treatment groups were nausea,
anemia, and fatigue (Table 3).
Immune-mediated AEs and infusion-related reactions (any
grade) occurred in 107 patients (26.4%) and 26 patients
(12.9%) in the pembrolizumab-combination and placebo-
combination groups, respectively. Grade 3-5 immune-
mediated AEs and infusion-related reactions occurred in
10.9% and 4.5%, respectively. The most frequently oc-
curring immune-mediated AEs in the pembrolizumab-
combination and placebo-combination groups were
Patients randomly allocated
(N = 616)
Pembrolizumab plus pemetrexed and platinum
Allocated                                                                   (n = 410; 66.6%)
Placebo plus pemetrexed and platinum
Allocated                                                                     (n = 206; 33.4%)
Study treatment
  Remaining on  1 component of allocated                  (n = 58; 14.1%) 
     study therapy 
  Discontinued all components of allocated                 (n = 352; 85.9%)
     study therapy
Study treatment
   Remaining on  1 component of allocated                     (n =7; 3.4%) 
      study therapy
   Discontinued all components of allocated                (n = 199; 96.6%) 
      study therapy
Subsequent therapy
   Alive, no subsequent therapy                                        (n = 8; 3.9%)a
   Died without subsequent therapy                              (n = 69; 33.5%)
 1 subsequent therapy                                             (n = 122; 59.2%)
 1 subsequent PD-1 or PD-L1 inhibitor                  (n = 111; 53.9%)
       On-study cross-over (pembrolizumab)                (n = 84; 40.8%)
Subsequent therapy
  Alive, no subsequent therapy                                      (n = 58; 14.1%)a
  Died without subsequent therapy                              (n = 111; 27.1%)
 1 subsequent therapy                                               (n = 183; 44.6%)
 1 subsequent PD-1 or PD-L1 inhibitor                      (n = 55; 13.4%)
FIG 1. Disposition of patients in the study. PD-1, programmed death-1; PD-L1, programmed death-ligand 1; (a) Includes 36 patients (8.8%) in the
pembrolizumab-combination arm and 4 patients (1.9%) in the placebo-combination arm who were alive without experiencing disease progression.
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hypothyroidism (7.9%), hyperthyroidism (4.9%), and
pneumonitis (4.9%; Table 3). Eight patients (2.0%) in
the pembrolizumab-combination group experienced ne-
phritis, 6 of whom had grade 3-4 events; there were no
additional grade 3-4 nephritis events since the prior
analysis (when 6/7 patients with nephritis had grade 3-4
events). No patients in the placebo-combination group ex-
perienced nephritis.
In patients with and without liver metastases, AEs of
grade $ 3 occurred in 69.2% and 72.4% of patients in
the pembrolizumab-combination group, respectively,
and 72.9% and 64.9% of patients in the placebo-
combination group, respectively; in patients with and
without brain metastases, AEs of grade $ 3 occurred in
80.0% and 70.1% of patients in the pembrolizumab-
combination group, respectively, and 63.6% and
67.5% of patients in the placebo-combination group,
respectively.
DISCUSSION
In this updated analysis from KEYNOTE-189, pem-
brolizumab plus pemetrexed-platinum continued to show
substantial improvement in OS and PFS versus placebo
plus pemetrexed-platinum when administered as first-line
therapy for metastatic nonsquamous NSCLC without sen-
sitizing EGFR/ALK alterations. Median OS and PFS were
approximately doubled in the pembrolizumab-combination
group, and this benefit was observed in patients with both
PD-L1‒positive and PD-L1‒negative disease, as well as in
patients with liver/brain metastases. PFS-2 was sub-
stantially improved in the pembrolizumab-combination
group compared with the placebo-combination group.
Safety outcomes were consistent with those from the
previous interim analysis and showed that the combina-
tion of pembrolizumab and pemetrexed-platinum has
a manageable toxicity profile. These data support use of
pembrolizumab plus pemetrexed-platinum as first-line
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FIG 2. Kaplan-Meier analysis of overall survival (OS) in the (A) overall intention-to-treat population and in subsets of patients by tumor proportion score (TPS):
(B) $ 50%, (C) 1%-49%, and (D) , 1%. HR, hazard ratio; NR, not reached; pembro, pembrolizumab.
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treatment of patients with metastatic nonsquamous
NSCLC.
Results from this updated analysis confirm and extend
those from the first interim analysis of KEYNOTE-189
(median follow-up, 10.5 months),6 in which the addition of
pembrolizumab resulted in significantly longer OS than
chemotherapy alone (HRs for OS, 0.56; 95% CI, 0.45 to
0.70 in this analysis v 0.49 in the prior analysis). We ob-
served continued OS benefit, with an estimated 2-year OS
rate of 46% in the pembrolizumab-combination group
versus 30% in the placebo-combination group, despite
54% of patients in the chemotherapy arm crossing over
to pembrolizumab monotherapy or other PD-1/PD-L1 in-
hibitors, underscoring the benefit of combining pem-
brolizumab with chemotherapy as first-line treatment in
advanced NSCLC. Notably, the 30% 2-year OS rate we
observed in the chemotherapy alone group was high
compared with historical 2-year OS rates of 14%-19% with
chemotherapy,12,13 likely reflecting the effect of crossover to
anti‒PD-(L)1 agents. The ongoing improvement in OS was
consistent with a long-term follow-up analysis from the
phase II KEYNOTE-021 cohort G study14 (pembrolizumab
plus pemetrexed-carboplatin v pemetrexed-carboplatin),
which showed long-term survival benefit with pem-
brolizumab (HR, 0.56; 95% CI, 0.32 to 0.95). Similar to OS
results, this updated analysis with longer follow-up also
confirmed the improved PFS and ORR observed with the
addition of pembrolizumab compared with placebo in the
first interim analysis of KEYNOTE-189.
Consistent with the initial analysis6 and with other studies
evaluating pembrolizumab monotherapy4,15,16 and com-
bination therapy5 in patients with advanced/metastatic
NSCLC, the magnitude of OS, PFS, and ORR benefit
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FIG 3. Kaplan-Meier analysis of progression-free survival in the (A) intention-to-treat population and in subsets of patients by programmed death-ligand 1
tumor proportion score (TPS): (B) $ 50%, (C) 1%-49%, and (D) , 1%. HR, hazard ratio; pembro, pembrolizumab.
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TPS $ 50%. We also continued to observe improved OS,
PFS, and ORR among patients with PD-L1 TPS , 1%;
importantly, with longer follow-up, the 95% CI for the PFS
HR did not cross 1.0 in the current analysis. Themagnitude
of OS and PFS benefit in patients with PD-L1 TPS , 1%
(HRs [95% CI] for OS and PFS, 0.52 [0.36 to 0.74] and
0.64 [0.47 to 0.89], respectively) was notable, particularly
because patients with PD-L1 TPS, 1%have a lower chance
of benefit with single-agent anti‒PD-1 therapy.1,3,15,16 In ad-
dition, survival was improved with the addition of pem-
brolizumab to chemotherapy in patients with PD-L1 TPS
1%-49%. Similar improvement in survival in this group of
patients has not been observed with single-agent anti‒PD-1
therapy compared with chemotherapy.4 It has been sug-
gested that improvements in outcome with regimens com-
bining a checkpoint inhibitor with platinum may be due, at
least in part, to induction of immunogenic cell death by
platinum-based chemotherapy, which leads to recruitment
of dendritic cells, downregulation of PD-L1 and PD-L2, and
enhanced tumor-specific T-cell activation.17 Additionally,
preclinical data suggest that pemetrexed can enhance
anticancer effects of immunotherapy.18 Our results suggest
that such mechanisms may contribute to improvements
in patient outcomes.
The substantial PFS and OS benefit and 46% 2-year OS rate
observed with pembrolizumab plus pemetrexed-platinum
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FIG 4. Kaplan-Meier analysis of progression-free survival-2 (PFS-2) in the (A) intention-to-treat population and in subsets of patients by programmed death-
ligand 1 (PD-L1) tumor proportion score (TPS): (B)$ 50%, (C) 1%-49%, (D), 1%. PFS-2 was defined as the time from randomization to objective tumor
progression on next-line treatment (including subsequent anti‒PD-[L]1 therapy) or death from any cause, whichever occurred first. HR, hazard ratio;
pembro, pembrolizumab.
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in KEYNOTE-189 underscore that chemotherapy plus
immunotherapy is an effective modality. Other phase III
studies have evaluated immunotherapy-immunotherapy
combination strategies for metastatic NSCLC. In CheckMate-
227 part 1, the study coprimary endpoints were met with
nivolumab plus ipilimumab versus chemotherapy (PFS
in TMB-$10mut/MB: HR, 0.58; 97.5% CI, 0.41 to 0.81;
P , .00119; OS in PD-L1–positive population: HR, 0.79;
97.72% CI, 0.65 to 0.96; P = .00720). In MYSTIC, the
primary OS and PFS endpoints with durvalumab with and
without tremelimumab versus chemotherapy were not
met (PD-L1-TC-expression-$ 25% population: durvalu-
mab v chemotherapy: OS HR, 0.76; 97.54% CI, 0.564
to 1.019; P = .036; durvalumab-plus-tremelimumab v
chemotherapy: OS HR, 0.85; 98.77% CI, 0.611 to 1.173;
P = .202; PFS HR, 1.05; 99.5% CI, 0.722 to 1.534;
P = .705).21
The OS benefit observed with the addition of pem-
brolizumab occurred despite 54% (111/206) of patients in
the placebo-combination group receiving subsequent
anti‒PD-(L)1 therapy, including 41% (84/206) who crossed
over to pembrolizumab monotherapy on-study (of 122
patients who received subsequent therapy, 91% received
anti–PD-[L]1 therapy). To assess the impact of pem-
brolizumab plus pemetrexed-platinum on subsequent
therapy, we evaluated PFS-2, defined as the time from
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FIG 5. Kaplan-Meier analysis of overall survival (OS) in patients (A) with and (B) without liver metastases and (C) with and (D) without brain
metastases. HR, hazard ratio; pembro, pembrolizumab.
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Any Grade Grade 3-5 Any Grade Grade 3-5
Experienced $ 1 adverse event 404 (99.8) 291 (71.9) 200 (99.0) 135 (66.8)
Led to discontinuation of any treatment component 136 (33.6) 33 (16.3)
Led to deatha 29 (7.2) 14 (6.9)
Adverse events occurring in $ 15% of patients in either group
Nausea 230 (56.8) 14 (3.5) 107 (53.0) 8 (4.0)
Anemia 192 (47.4) 74 (18.3) 98 (48.5) 32 (15.8)
Fatigue 172 (42.5) 28 (6.9) 78 (38.6) 7 (3.5)
Constipation 144 (35.6) 4 (1.0) 67 (33.2) 1 (0.5)
Diarrhea 128 (31.6) 21 (5.2) 44 (21.8) 6 (3.0)
Decreased appetite 120 (29.6) 5 (1.2) 64 (31.7) 2 (1.0)
Neutropenia 112 (27.7) 65 (16.0) 51 (25.2) 25 (12.4)
Vomiting 105 (25.9) 16 (4.0) 47 (23.3) 6 (3.0)
Cough 100 (24.7) 0 61 (30.2) 0
Dyspnea 98 (24.2) 17 (4.2) 54 (26.7) 10 (5.0)
Peripheral edema 88 (21.7) 2 (0.5) 29 (14.4) 0
Pyrexia 88 (21.7) 1 (0.2) 32 (15.8) 0
Asthenia 87 (21.5) 27 (6.7) 49 (24.3) 7 (3.5)
Rash 87 (21.5) 8 (2.0) 26 (12.9) 3 (1.5)
Thrombocytopenia 75 (18.5) 34 (8.4) 30 (14.9) 14 (6.9)
Lacrimation increased 74 (18.3) 0 22 (10.9) 0
Back pain 66 (16.3) 6 (1.5) 26 (12.9) 4 (2.0)
Immune-mediated adverse eventsb 107 (26.4) 44 (10.9) 26 (12.9) 9 (4.5)
Hypothyroidism 32 (7.9) 2 (0.5) 5 (2.5) 0
Hyperthyroidism 20 (4.9) 0 6 (3.0) 0
Pneumonitis 20 (4.9) 12 (3.0) 6 (3.0) 4 (2.0)
Colitis 12 (3.0) 6 (1.5) 0 0
Infusion reactions 11 (2.7) 1 (0.2) 3 (1.5) 0
Severe skin reactions 9 (2.2) 9 (2.2) 5 (2.5) 4 (2.0)
Nephritis 8 (2.0) 6 (1.5) 0 0
Hepatitis 5 (1.2) 4 (1.0) 0 0
Hypophysitis 3 (0.7) 0 0 0
Myositis 3 (0.7) 0 0 0
Pancreatitis 3 (0.7) 2 (0.5) 0 0
Encephalitis 2 (0.5) 2 (0.5) 0 0
Type I diabetes mellitus 2 (0.5) 2 (0.5) 0 0
Adrenal insufficiency 1 (0.2) 1 (0.2) 1 (0.5) 1 (0.5)
Myocarditis 1 (0.2) 1 (0.2) 0 0
Thyroiditis 1 (0.2) 0 0 0
NOTE. Reported in all patients who received $ 1 dose of study treatment. Data are No. (%).
aEight patients (2.0%) in the pembrolizumab-combination group and 2 patients in the placebo-combination group died of adverse events
attributed by the investigator to study treatment.
bEvents were based on a list from the sponsor and considered regardless of attribution to treatment or immune relatedness by the investigator.
1514 © 2020 by American Society of Clinical Oncology Volume 38, Issue 14
Gadgeel et al
Downloaded from ascopubs.org by Universita Studi Di Torino on August 27, 2020 from 130.192.222.027
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
treatment or death from any cause, whichever occurred
first.11 For the first time, we showed that first-line pem-
brolizumab plus pemetrexed-platinum improved PFS-2,
which was approximately doubled for patients in the
pembrolizumab-combination group. This PFS-2 outcome
demonstrates that treatment effects observed in the first-
line setting were maintained into the next line of therapy.
Moreover, despite the high crossover rate, we observed
improved survival outcomes in patients with metastatic
nonsquamous NSCLC who initiated pembrolizumab as
first-line treatment in combination with chemotherapy
compared with those who initiated chemotherapy first and
then received pembrolizumab (or another anti–PD-[L]1
agent) postprogression. These results are consistent with
the PFS-2 analysis for pembrolizumab monotherapy in
KEYNOTE-02422 and support preferential use of pem-
brolizumab in the first-line setting.
Liver and brain metastases are poor prognostic factors in
patients with NSCLC.8,9 The efficacy of immunotherapy
treatment effect in these patient populations has been
uncertain, with results from one study suggesting reduced
benefit in patients with liver metastases.10 Consistent with
poor prognosis among patients with brain or liver metas-
tases, we observed shorter median OS times among these
patients compared with patients without brain or liver me-
tastases. However, this poorer prognosis did not diminish
the treatment effect associated with the addition of pem-
brolizumab to pemetrexed-platinum: HRs for OS and PFS
were similar among patients with and without brain me-
tastases and among patients with and without liver me-
tastases. Outcomes in patients with liver metastases were
also evaluated in the IMpower13023 and IMpower15024,25
studies, which evaluated atezolizumab plus platinum-based
chemotherapy versus platinum-based chemotherapy alone
and atezolizumab plus bevacizumab plus platinum-based
chemotherapy versus atezolizumab plus platinum-based
chemotherapy versus bevacizumab plus platinum-based
chemotherapy, respectively, in patients with advanced
nonsquamous NSCLC. In these 2 studies, OS benefit in
patients with liver metastases was only observed among
patients who received atezolizumab plus bevacizumab plus
chemotherapy.
Addition of pembrolizumab to pemetrexed-platinum con-
tinued to show a manageable safety profile after a mean
treatment duration of 9.8 months. Despite longer follow-up
with this analysis, no new safety signals were identified,
including no additional immune-mediated AEs beyond those
previously observed with pembrolizumab monotherapy.3,4
The proportion of patients experiencing grade 3-5 AEs
was similar between the pembrolizumab-combination and
placebo-combination groups, suggesting that addition of
pembrolizumab to standard chemotherapy was associated
with acceptable toxicity. Consistent with the primary analysis,
a greater percentage of patients in the pembrolizumab-
combination versus placebo-combination group experi-
enced AEs of acute kidney injury and nephritis; however,
despite longer treatment exposure, only 1 additional event
of grade 2 nephritis occurred. AEs were generally similar
between patients in the pembrolizumab-combination and
placebo-combination groups across subgroups with or
without liver/brain metastases.
In summary, after median follow-up of approximately
2 years, pembrolizumab plus pemetrexed-platinum
resulted in substantially longer OS, PFS, and PFS-2
and a higher response compared with placebo plus
pemetrexed-platinum in patients with metastatic non-
squamous NSCLC without sensitizing EGFR/ALK alter-
ations. Survival benefit was observed across all PD-L1 TPS
groups and in patients with liver/brain metastases. Safety
and tolerability results were comparable with the first in-
terim analysis (10.5 months median follow-up). These
results support pembrolizumab plus pemetrexed-platinum
as a standard-of-care first-line therapy among patients with
metastatic nonsquamous NSCLC without sensitizing EGFR/
ALK alterations, regardless of tumor PD-L1 expression.
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